Vitalchat Names Michael Raymer as New CEO

1 year ago

Seasoned healthcare executive will lead next phase of growth for virtual nursing and telehealth growth company.ASHBURN, VA / ACCESSWIRE /…

Women’s Care Announces New State-of-the-Art Facility in Carrollwood, FL

1 year ago

TAMPA, FL / ACCESSWIRE / October 18, 2024 / Women's Care, a leading national women's health physician group, is expanding…

Sarah Dolan Joins Women’s Care Florida as New OB/GYN

1 year ago

TAMPA, FL / ACCESSWIRE / October 18, 2024 / Women's Care is excited to announce the addition of Dr. Sarah…

Deanna Caminiti, MD Joins Women’s Care in Lakewood Ranch, Florida

1 year ago

BRADENTON, FL / ACCESSWIRE / October 18, 2024 / Women's Care is excited to announce the addition of Dr. Deanna…

Jean Health Announces Expansion into Australia: Solving Urgent Rural Maternity Care Needs

1 year ago

Jean Health has announced its expansion into Australia to address the urgent maternity care needs in rural areas. The company…

Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit

1 year ago

SARASOTA, Fla., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Oragenics Inc. (NYSE American: OGEN), a company focused on developing new treatments…

FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases

1 year ago

HOUSTON, Oct. 18, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) (“FibroBiologics”) and Charles River Laboratories (“Charles River”), a leading…

SeaStar Medical Announces that Enrollment in its Adult Acute Kidney Injury Pivotal Trial Has Exceeded the Halfway Point Toward an Interim Analysis

1 year ago

The pace of patient enrollment has significantly accelerated following a summertime slowdown DENVER, Oct. 18, 2024 (GLOBE NEWSWIRE) -- SeaStar…

Vivos Inc. Certifies New Clinic for IsoPet® Precision Radionuclide TherapyTM

1 year ago

Richland WA N, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc. Certifies new clinic for IsoPet…

Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

1 year ago

ZORYVE foam represents the first topical treatment for seborrheic dermatitis with a new mechanism of action approved in Canada in…